MADRID A personalized mRNA cancer vaccine reduced the risk of disease recurrence in patients with melanoma by 42% compared to a standard treatment, according to a large clinical trial conducted by th… [+886 chars]Read More
Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial STAT
